Literature DB >> 15831699

Crystal structure of the Jak3 kinase domain in complex with a staurosporine analog.

Titus J Boggon1, Yiqun Li, Paul W Manley, Michael J Eck.   

Abstract

Jak (Janus kinase) family nonreceptor tyrosine kinases are central mediators of cytokine signaling. The Jak kinases exhibit distinct cytokine receptor association profiles and so transduce different signals. Jak3 expression is limited to the immune system, where it plays a key role in signal transduction from cytokine receptors containing the common gamma-chain, gammac. Patients unable to signal via gammac present with severe combined immunodeficiency (SCID). The finding that Jak3 mutations result in SCID has made it a target for development of lymphocyte-specific immunosuppressants. Here, we present the crystal structure of the Jak3 kinase domain in complex with staurosporine analog AFN941. The kinase domain is in the active conformation, with both activation loop tyrosine residues phosphorylated. The phosphate group on pTyr981 in the activation loop is in part coordinated by an arginine residue in the regulatory C-helix, suggesting a direct mechanism by which the active position of the C-helix is induced by phosphorylation of the activation loop. Such a direct coupling has not been previously observed in tyrosine kinases and may be unique to Jak kinases. The crystal structure provides a detailed view of the Jak3 active site and will facilitate computational and structure-directed approaches to development of Jak3-specific inhibitors.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15831699      PMCID: PMC1895152          DOI: 10.1182/blood-2005-02-0707

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  38 in total

Review 1.  Janus kinases: components of multiple signaling pathways.

Authors:  S G Rane; E P Reddy
Journal:  Oncogene       Date:  2000-11-20       Impact factor: 9.867

2.  PRODRG: a tool for high-throughput crystallography of protein-ligand complexes.

Authors:  Alexander W Schüttelkopf; Daan M F van Aalten
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2004-07-21

3.  Automated refinement for protein crystallography.

Authors:  V S Lamzin; K S Wilson
Journal:  Methods Enzymol       Date:  1997       Impact factor: 1.600

4.  Insulin receptor tyrosine kinase activity and phosphorylation of tyrosines 1162 and 1163 are required for insulin-increased prolactin gene expression.

Authors:  Kirsten K Jacob; Jonathan Whittaker; Frederick M Stanley
Journal:  Mol Cell Endocrinol       Date:  2002-01-15       Impact factor: 4.102

5.  Distinct tyrosine phosphorylation sites in JAK3 kinase domain positively and negatively regulate its enzymatic activity.

Authors:  Y J Zhou; E P Hanson; Y Q Chen; K Magnuson; M Chen; P G Swann; R L Wange; P S Changelian; J J O'Shea
Journal:  Proc Natl Acad Sci U S A       Date:  1997-12-09       Impact factor: 11.205

6.  Prevention of organ allograft rejection by a specific Janus kinase 3 inhibitor.

Authors:  Paul S Changelian; Mark E Flanagan; Douglas J Ball; Craig R Kent; Kelly S Magnuson; William H Martin; Bonnie J Rizzuti; Perry S Sawyer; Bret D Perry; William H Brissette; Sandra P McCurdy; Elizabeth M Kudlacz; Maryrose J Conklyn; Eileen A Elliott; Erika R Koslov; Michael B Fisher; Timothy J Strelevitz; Kwansik Yoon; David A Whipple; Jianmin Sun; Michael J Munchhof; John L Doty; Jeffrey M Casavant; Todd A Blumenkopf; Michael Hines; Matthew F Brown; Brett M Lillie; Chakrapani Subramanyam; Chang Shang-Poa; Anthony J Milici; Gretchen E Beckius; James D Moyer; Chunyan Su; Thasia G Woodworth; Anderson S Gaweco; Chan R Beals; Bruce H Littman; Douglas A Fisher; James F Smith; Panayiotis Zagouras; Holly A Magna; Mary J Saltarelli; Kimberly S Johnson; Linda F Nelms; Shelley G Des Etages; Lisa S Hayes; Thomas T Kawabata; Deborah Finco-Kent; Deanna L Baker; Michael Larson; Ming-Sing Si; Ricardo Paniagua; John Higgins; Bari Holm; Bruce Reitz; Yong-Jie Zhou; Randall E Morris; John J O'Shea; Dominic C Borie
Journal:  Science       Date:  2003-10-31       Impact factor: 47.728

7.  Constitutive activation of JAKs and STATs in BCR-Abl-expressing cell lines and peripheral blood cells derived from leukemic patients.

Authors:  S K Chai; G L Nichols; P Rothman
Journal:  J Immunol       Date:  1997-11-15       Impact factor: 5.422

Review 8.  Jak3 and the pathogenesis of severe combined immunodeficiency.

Authors:  John J O'Shea; Matthew Husa; Denise Li; Sigrun R Hofmann; Wendy Watford; Joseph L Roberts; Rebecca H Buckley; Paul Changelian; Fabio Candotti
Journal:  Mol Immunol       Date:  2004-07       Impact factor: 4.407

9.  Janus kinase 3 (JAK3) deficiency: clinical, immunologic, and molecular analyses of 10 patients and outcomes of stem cell transplantation.

Authors:  Joseph L Roberts; Andrea Lengi; Stephanie M Brown; Min Chen; Yong-Jie Zhou; John J O'Shea; Rebecca H Buckley
Journal:  Blood       Date:  2003-11-13       Impact factor: 22.113

10.  Jak-STAT signaling induced by the v-abl oncogene.

Authors:  N N Danial; A Pernis; P B Rothman
Journal:  Science       Date:  1995-09-29       Impact factor: 47.728

View more
  48 in total

1.  Modulation of activation-loop phosphorylation by JAK inhibitors is binding mode dependent.

Authors:  Rita Andraos; Zhiyan Qian; Débora Bonenfant; Joëlle Rubert; Eric Vangrevelinghe; Clemens Scheufler; Fanny Marque; Catherine H Régnier; Alain De Pover; Hugues Ryckelynck; Neha Bhagwat; Priya Koppikar; Aviva Goel; Lorenza Wyder; Gisele Tavares; Fabienne Baffert; Carole Pissot-Soldermann; Paul W Manley; Christoph Gaul; Hans Voshol; Ross L Levine; William R Sellers; Francesco Hofmann; Thomas Radimerski
Journal:  Cancer Discov       Date:  2012-05-03       Impact factor: 39.397

2.  Transforming JAK1 mutations exhibit differential signalling, FERM domain requirements and growth responses to interferon-γ.

Authors:  Geoff M Gordon; Que T Lambert; Kenyon G Daniel; Gary W Reuther
Journal:  Biochem J       Date:  2010-12-01       Impact factor: 3.857

3.  JAK2T875N is a novel activating mutation that results in myeloproliferative disease with features of megakaryoblastic leukemia in a murine bone marrow transplantation model.

Authors:  Thomas Mercher; Gerlinde Wernig; Sandra A Moore; Ross L Levine; Ting-Lei Gu; Stefan Fröhling; Dana Cullen; Roberto D Polakiewicz; Olivier A Bernard; Titus J Boggon; Benjamin H Lee; D Gary Gilliland
Journal:  Blood       Date:  2006-06-27       Impact factor: 22.113

4.  Activity of dual SRC-ABL inhibitors highlights the role of BCR/ABL kinase dynamics in drug resistance.

Authors:  Mohammad Azam; Valentina Nardi; William C Shakespeare; Chester A Metcalf; Regine S Bohacek; Yihan Wang; Raji Sundaramoorthi; Piotr Sliz; Darren R Veach; William G Bornmann; Bayard Clarkson; David C Dalgarno; Tomi K Sawyer; George Q Daley
Journal:  Proc Natl Acad Sci U S A       Date:  2006-06-05       Impact factor: 11.205

5.  Structures of lung cancer-derived EGFR mutants and inhibitor complexes: mechanism of activation and insights into differential inhibitor sensitivity.

Authors:  Cai-Hong Yun; Titus J Boggon; Yiqun Li; Michele S Woo; Heidi Greulich; Matthew Meyerson; Michael J Eck
Journal:  Cancer Cell       Date:  2007-03       Impact factor: 31.743

6.  Examining the chirality, conformation and selective kinase inhibition of 3-((3R,4R)-4-methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile (CP-690,550).

Authors:  Jian-kang Jiang; Kamran Ghoreschi; Francesca Deflorian; Zhi Chen; Melissa Perreira; Marko Pesu; Jeremy Smith; Dac-Trung Nguyen; Eric H Liu; William Leister; Stefano Costanzi; John J O'Shea; Craig J Thomas
Journal:  J Med Chem       Date:  2008-12-25       Impact factor: 7.446

Review 7.  Jak2 inhibitors: rationale and role as therapeutic agents in hematologic malignancies.

Authors:  Jacqueline Sayyah; Peter P Sayeski
Journal:  Curr Oncol Rep       Date:  2009-03       Impact factor: 5.075

Review 8.  Molecular pathways: molecular basis for sensitivity and resistance to JAK kinase inhibitors.

Authors:  Sara C Meyer; Ross L Levine
Journal:  Clin Cancer Res       Date:  2014-02-28       Impact factor: 12.531

9.  Structural basis for the autoinhibition of focal adhesion kinase.

Authors:  Daniel Lietha; Xinming Cai; Derek F J Ceccarelli; Yiqun Li; Michael D Schaller; Michael J Eck
Journal:  Cell       Date:  2007-06-15       Impact factor: 41.582

10.  Identification of a novel inhibitor of JAK2 tyrosine kinase by structure-based virtual screening.

Authors:  Róbert Kiss; Tímea Polgár; Annet Kirabo; Jacqueline Sayyah; Nicholas C Figueroa; Alan F List; Lubomir Sokol; Kenneth S Zuckerman; Meghanath Gali; Kirpal S Bisht; Peter P Sayeski; György M Keseru
Journal:  Bioorg Med Chem Lett       Date:  2009-05-05       Impact factor: 2.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.